Screening for in vitro and in vivo antitumor activities of the mushroom Agaricus blazei

Nutrition and Cancer

Volumn 61, Issue 2, 2009, Pages 245-250

  Ziliotto, Liane ^a   Pinheiro, Fabriciano ^a   Barbisan, Luís Fernando ^a   Rodrigues, Maria Aparecida Marchesan ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID ETHYL ESTER; AGARICUS BLAZEI EXTRACT; BIOLOGICAL MARKER; BUTANOL; CARCINOGEN; DICHLOROMETHANE; DIMETHYLHYDRAZINE; METHANOL;

AGARICUS BLAZEI; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; AQUEOUS SOLUTION; ARTICLE; CANCER CELL CULTURE; CANCER INCIDENCE; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; CRYPT CELL; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MUSHROOM; NONHUMAN; RAT; TREATMENT DURATION; WISTAR RAT;

ADENOCARCINOMA; AGARICUS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL LINE, TUMOR; COLONIC NEOPLASMS; DIET; FEMALE; HUMANS; MALE; RATS; RATS, WISTAR;

AGARICUS BLAZEI; BASIDIOMYCOTA; RATTUS; RATTUS NORVEGICUS;

EID: 61649105552     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1080/01635580802395717     Document Type: Article

References (43)

1. Ahn WS, Kim DJ, Chae GT, Lee J-M, Bae S-M, et al.: Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int J Gynecol Cancer 14, 589-594, 2004.
2. Yoshimura K, Ueda N, Ichioka K, Matsui Y, Terai A, et al.: Use of complementary and alternative medicine by patients with urologic cancer: a prospective study at a single Japanese institution. Support Care Cancer 13, 685-690, 2005.
3. Talcott JA, Clark JA, and Lee IP: Measuring perceived effects of drinking an extract of basidiomycetes Agaricus blazei Murill: a survey of Japanese consumers with cancer. BMC Complement Altern Med 7, 32, 2007.
4. Mizuno T, Saito H, Nishitoba T, Kawagishi H: Antitumor-active substances from mushrooms. Food Rev Int 11, 23-61,1995.
5. Wasser SP and Weiss AL: Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: modern perspective. Crit Rev Immunol 19, 65-96, 1999.
6. Borchers AT, Keen CL, and Gershwin ME: Mushrooms, tumors, and immunity: an update. Exp Biol Med 229, 393-406, 2004.
7. Fujimiya Y, Suzuki Y, Oshiman K, Kobori H, Moriguchi K, et al.: Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycet, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis. Cancer Immunol Immunother 46, 147-159,1998.
8. Jin C-Y, Moon D-O, Choi YH, Lee J-D, Kim G-Y: Bcl-2 and caspase-3 are major regulators in Agaricus blazei-induced human leukemic U937 cell apoptosis through dephosphorylation of Akt. Biol Pharm Bul 30, 1432-1437, 2007.
9. Gao L, Sun Y, Chen C, Xi Y, Wang J, et al.: Primary mechanism of apoptosis induction in a leukemia cell line by fraction FA-2-b-beta prepared from the mushroom Agaricus blazei Murill. Braz J Med Biol Res 40, 1545-1555, 2007.
10. Itoh H, Ito H, Amano H, and Noda H: Inhibitory action of a (1→6)-β-D-glucan-protein complex (FIII-2-b) isolated from Agaricus blazei Murill ("Himematsutake") on Meth A fibrosarcoma-bearing mice and its antitumor mechanism. Jpn J Pharmacol 66, 265-271, 1994.
11. Takaku T, Kimura Y, and Okuda H. Isolation of an antitumor compound from Agaricus blazei Murill and its mechanism of action. J Nutr 131, 1409-1413, 2001.
12. Kobayashi H, Yoshida R, Kanada Y, Fukuda Y, Yagyu T, et al.: Suppressing effects of daily oral supplementation of beta-glucan extracted from Agaricus blazei Murill on spontaneous and peritoneal disseminated metastasis in mouse model. J Cancer Res Clin Oncol 13, 1527-1538, 2005.
13. Barbisan LF, Miyamoto M, Scolastici C, Salvadori DMF, Ribeiro LR, et al.: Influence of aqueous extract of Agaricus blazei on rat liver toxicity induced by different doses of diethylnitrosamine. J Ethnopharmacol 83, 25-32, 2002.
14. Pinheiro F, Faria RR, Camargo JLV, Spinardi-Barbisan ALT, Eira AF, et al.: Chemoprevention of preneoplastic liver foci development by dietary mushroom Agaricus blazei Murrill in the rat. Food Chem Toxicol 41, 1543-1550, 2003.
15. Delmanto RD, Lima PLA, Sugui MM, Eira AF, Salvadori DMF, et al.: Antimutagenic effect of Agaricus blazei Murrill mushroom on the genotoxicity induced by cyclophosphamide. Mutat Res 496, 15-21, 2001.
16. Menoli RCRN, Mantovani MS, Ribeiro LR, Speit G, and Jordão BQ: Antimutagenic effects of the mushroom Agaricus blazei Murrill extracts on V79 cells. Mutat Res 496, 5-13, 2001.
17. Oliveira JM, Jordão BQ, Ribeiro LR, Eira AF, and Mantovani MS: Antigentoxic effect of aqueous extracts of sun mushroom (Agaricus blazei Murrill lineage 99/26) in mammalian cells in vitro. Food Chem Toxicol 40, 1775-1780, 2002.
18. Potter JD: Colorectal cancer: molecules and populations. J Natl Cancer Inst 91, 916-932, 1999.
19. Willett WC: Diet and cancer: one view at the start of the millennium. Cancer Epidemiol Biomarkers Prev 10, 3-8, 2001.
20. Bingham S and Riboli E: Diet and cancer - the European prospective investigation into cancer and nutrition. Nat Rev Cancer 4, 206-215, 2004.
21. Sugimura T, Terada M, Yokota J, Hirohashi S, and Wakabayashi K: Multiple genetic alterations in human carcinogenesis. Environ Health Perspect 98, 5-12, 1992.
22. Bird RP and Good CK: The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer. Toxicol Lett 112, 395-402, 2000.
23. Rodrigues MAM, Silva LAG, Salvadori DMF, Camargo JLV, and Montenegro MR: Aberrant crypt foci and colon cancer: comparison between a short and medium-term bioassay for colon carcinogenesis using dimethyl-hydrazine in Wistar rats. Braz J Med Biol Res 35, 351-355, 2002.
24. Mori M, Hata K, Yamada Y, Kuno T, and Hara A: Significance and role of early-lesions in experimental colorectal carcinogenesis. Chem Biol Interact 155, 1-9, 2005.
25. Rudolph RE, Dominitz JA, Lampe JW, Levy L, Qu P, et al.: Risk factors for colorectal cancer in relation to number and size of aberrant crypt foci in humans. Cancer Epidemiol Biomarkers Prev 14, 605-608, 2005.
26. Stevens RG, Swede H, and Rosenberg DW: Epidemiology of colonic aberrant crypt foci: review and analysis of existing studies. Cancer Lett 252, 171-183, 2007.
27. Corpet DE and Taché S: Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 43, 1-21, 2002.
28. Corpet DE and Pierre F: How good are rodent models of carcinogenesis in predicting efficacy in humans?: a systematic review and meta-analysis of colon chemoprevention in rats, mice and men. Eur J Cancer 41, 1911-1922, 2005.
29. Taché S, Ladam A, and Corpet DE: Chemoprevention of aberrant crypt foci in the colon of rats by dietary onion. Eur J Cancer 43, 454-458, 2007.
30. Boateng J, Verghese M, Shackelford L, Walker LT, Khatiwada J, et al.: Selected fruits reduce azoxymethane (AOM)-induced aberrant crypt foci (ACF) in Fisher 344 male rats. Food Chem Toxicol 45, 725-732, 2007.
31. Izawa S and Inoue Y: A screening system for antioxidants using thioredoxin-deficient yeast: discovery of thermostable antioxidant activity from Agaricus blazei Murill. Appl Microbiol Cell Physiol 64, 537-542, 2004.
32. Bellini MF, Angeli JP, Matuo R, Terezan AP, Ribeiro LR, et al.: Antigeno-toxicity of Agaricus blazei mushroom organic and aqueous extracts in chromosomal aberration and cytokinesis block micronucleus assays in CHO-k1 and HTC cells. Toxicol In Vitro 20, 355-360, 2006.
33. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, et al.: Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Nat Cancer Inst 83, 757-776, 1991.
34. Petinari L, Kohn LK, Carvalho JH, and Genari SC: Cytotoxicity of tamoxifen in normal and tumoral cell lines and its ability to induce cellular transformation in vitro. Cell Biol Int 28, 531-539, 2004.
35. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, et al.: New colorimetric cytotoxicity assay for anti-cancer-drug screening. J Natl Cancer Inst 82, 1107-1112, 1990.
36. Kuroiwa Y, Nishikawa A, Imazawa T, Kanki K, Kitamura Y, et al.: Lack of subchronic toxicity of an aqueous extract of Agaricus blazei Murrill in F344 rats. Food Chem Toxicol 43, 1047-1053, 2005.
37. Lee IP, Kang BH, Roth JK, and Kim JR: Lack of carcinogenicity of lyophilized Agaricus blazei Murill in a F344 rat two year bioassay. Food Chem Toxicol 46, 87-95, 2008.
38. Siu IM, Pretlow TG, Amini SB, and Pretlow TP: Identification of dysplasia in human colonic aberrant crypt foci. Am J Pathol 150, 1805-1813, 1997.
39. Kluck RM, Bossy-Wetzel E, Green DR, and Newmeyer DD: The release of cytochrome C from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 275, 1132-1136, 1997.
40. Mow BM, Blajeski AL, Chandra J, and Kaufmann SH: Apoptosis and the response to anticancer therapy. Curr Opin Oncol 13, 453-462, 2001.
41. Ziliotto L, Barbisan LF, and Rodrigues MAM:, 2008. Lack of chemoprevention of dietary Agaricus blazei against rat colonic aberrant crypt foci. Human Exp Toxicol 27, 505-511, 2008.
42. Barbisan LF, Spinardi-Barbisan ALT, Moreira ELT, Salvadori DMF, Ribeiro LR, et al.: Agaricus blazei (Himematsutake) does not alter the development of rat diethylnitrosamine- initiated hepatic preneoplastic foci. Cancer Sci 94, 188-192, 2003.
43. Yuminamochi E, Koike T, Takeda K, Horiuchi I, and Okumura K: Interleukin-12 and interferon- gamma-mediated natural killer cell activation by Agaricus blazei Murill. Immunology 121, 197-206, 2007.